Background/Objectives: Brolucizumab is a humanized single-chain antibody fragment with a molecular weight of approximately 26 kilodaltons (scFv, ~26 kDa) targeting all VEGF-A isoforms. Intravitreal brolucizumab (6 mg) is FDA-approved for neovascular age-related macular degeneration (nAMD) (2019) and diabetic macular edema (DME) (2022). We systematically review the literature on brolucizumab for nAMD and DME, focusing on efficacy, safety, pharmacokinetics, real-world outcomes, and cost-effectiveness in adult and pediatric patients. Methods: Our method involves a comprehensive literature search of PubMed, Embase, Scopus, Cochrane, and related databases (through late 2024) using terms including “brolucizumab,” “Beovu,” “neovascular AMD,” “diabetic macular edema,” “safety,” “pharmacokinetics,” and “pediatric.” High-quality clinical trials, meta-analyses, regulatory documents, and real-world studies were prioritized. Results: In pivotal Phase III trials (HAWK/HARRIER for nAMD), brolucizumab 6 mg demonstrated non-inferior visual acuity (VA) gains to aflibercept, with >50% of eyes maintained on 12-week dosing and greater retinal fluid reduction. In DME trials (KESTREL/KITE), brolucizumab was similarly non-inferior to aflibercept for VA and showed superior anatomic drying, with 33–48% of eyes maintained on ≥12-week intervals. However, brolucizumab use has been associated with intraocular inflammation (IOI), retinal vasculitis, and vascular occlusion: clinical trials and post hoc analyses reported higher rates of these events than comparator agents. Real-world cohorts found IOI in ~4–10% of treated eyes, often occurring early (within 3 months) after initiation. Conclusions: In conclusion, Brolucizumab is an effective anti-VEGF option for nAMD and DME, providing durable anatomic control with fewer injections. Non-inferior vision outcomes and superior fluid resolution have been demonstrated. However, it carries a distinct risk of IOI and occlusive vasculitis, necessitating careful patient selection, dosing, and monitoring.

Background/Objectives: Central retinal artery occlusion (CRAO) is a vision-threatening condition with limited evidence-based treatment options. Hyperbaric oxygen therapy (HBOT) has emerged as a potential intervention, but its efficacy remains debated. This systematic review and meta-analysis evaluated the therapeutic efficacy and safety of HBOT in CRAO. Methods: Relevant studies were identified across seven databases using optimized Boolean and MeSH-based strategies. Eligible studies evaluated HBOT in CRAO and reported visual or safety outcomes. Extracted data included demographics, intervention details, treatment timing, visual acuity outcomes, and adverse events. Risk of bias was assessed using ROBINS-I. Visual acuity outcomes were standardized to logMAR whenever directly reported or convertible, and subgroup analyses were stratified by HBOT initiation time (12 h), study type, and baseline visual severity when reported. A random-effects model was used, and pooled estimates were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Results: Twelve studies were included. The pooled efficacy analysis favored HBOT (OR = 0.47; 95% CI: 0.26–0.87; p = 0.02), although heterogeneity was substantial (Tau² = 0.64; I² = 78%). Stratified synthesis showed that studies in which HBOT was initiated within 12 h consistently reported greater visual improvement, whereas delayed or variably timed treatment showed attenuated and inconsistent benefits. After outcome harmonization, studies reporting logMAR-compatible data generally demonstrated clinically relevant visual improvement, while adverse-event rates did not differ significantly between HBOT and non-HBOT groups (OR = 0.70; 95% CI: 0.43–1.16; p = 0.17; I² = 0%). Conclusions: HBOT appears most beneficial when initiated early, particularly within the first 12 h. However, heterogeneity in treatment timing, study design, and baseline severity reporting limits the certainty of these results and supports the need for standardized outcome reporting and protocol-driven prospective studies.

To describe a case of mechanical eye globe penetration resulting in subretinal and vitreous hemorrhages and retinal tear that occurred immediately following a periorbital hyaluronic acid (HA) filler injection, and to outline acute management and early anatomical outcome. A healthy 26-year-old female presented to the emergency department with the sudden onset of floaters in her left eye immediately after receiving a hyaluronic acid filler injection to the eyelid area. The best corrected visual acuity (BCVA) was 20/20 Snellen equivalent in both eyes. Ophthalmic examination showed a dense subconjunctival hemorrhage temporally and inferiorly in the left eye. The fundus examination revealed localized vitreous and subretinal hemorrhage along with an inferior retinal tear, confirming globe penetration. The patient was treated with laser retinopexy and topical antibiotics. Over serial follow-up, she experienced gradual symptom improvement, and imaging showed resolution of hemorrhage with well-formed laser scars. There were no signs of infection or retinal detachment. This case report highlights the risk of direct mechanical eye globe penetration associated with periocular HA filler injections. Early assessment and prompt ophthalmologic care are essential for saving vision and avoiding additional complications. Cosmetic professionals must follow safe injection practices and be aware of the possible complications to avoid injuries that might impair vision.

A BSTRACT: Background: Refractive errors are the most common ocular problems affecting all age groups. They are considered a public health challenge. Recent studies indicated that refractive errors are the leading cause of visual impairment and the second cause of visual loss worldwide, as 43% of visual impairments were attributed to refractive errors. The aim of the study was to determine the prevalence of refractive errors among students of the College of Medicine and Applied Medical Sciences College, University of Bisha, Saudi Arabia. Methods: A descriptive cross-sectional study was used. A total of 212 participants, comprising 106 (50%) males and 106 (50%) females, were involved in the study. The age range of the participants was between 18 and 25 years, with a mean age of 20.6 ± 1.8 years. Data were collected using a predesigned online electronic questionnaire. Results: The result of the study showed that 127 (59.9%) of the respondents consulted an ophthalmologist with 60 of them within the last 1 year, 20 between 2 and 3 years and the remaining 47 more than 3 years. Short sightedness had the highest prevalence with 38 (17.9%) reported cases of RE, followed by short sightedness with astigmatism 28 (13.2%), and astigmatism without other defects 24 (11.3%) while 12 (5.7%) participants reported long sightedness. Social media was the most reported source of information (55.1%; 27) followed by friends (28.6%; 14), and ophthalmologist (16.3%; 8). Conclusion: The present study revealed that the prevalence of refractive errors among students in the University of Bisha was high, especially myopia and astigmatism. There was no significant difference regarding gender, age, or course of study in the prevalence of RE among the students of the University of Bisha.

Background/Objectives: To assess the knowledge, attitudes, and practices of ophthalmologists in Saudi Arabia towards genomic medicine and genetic testing, in light of the growing significance of genomics in ophthalmology and the national transition towards precision medicine. Methods: A cross-sectional, questionnaire-based survey was conducted among ophthalmologists, including consultants, specialists, fellows, and residents, across Saudi Arabia. The questionnaire included four domains: demographics, knowledge of genomic principles and gene therapy, self-rated confidence in genetic tasks (scored 1–10), and attitudes toward genetic testing. Data were analyzed using descriptive and inferential statistics, with subgroup comparisons performed using chi-square tests and t-tests/ANOVA. Results: A total of 115 ophthalmologists participated (46% male, 54% female; mean age 34 years; mean post-board experience 4 years). Most were consultants (40%) and practiced in Riyadh (52%). Knowledge was variable: 92% correctly identified human chromosome count, and 99% recognized autosomal recessive inheritance, but only 9% answered DNA base-pairing correctly, and 54% recognized mitochondrial inheritance. Confidence was highest for referral to specialists (mean 7.3/10) and lowest for test selection and counseling (4.7/10). The internet was the primary knowledge source among our sample (65%). The majority of individuals had positive attitudes towards genomic medicine: 90% believed testing was beneficial, 89% considered it enhanced health outcomes, and 89% indicated they would undergo testing themselves. On the other hand, 77% indicated difficulty in access, 91% strongly concurred on the significance of privacy and confidentiality, and more than half expressed concerns regarding misuse and bias. Conclusions: Ophthalmologists in Saudi Arabia acknowledge the importance of genetics. Yet, there are substantial gaps in knowledge and familiarity with genomic medicine and genetic testing. To overcome these challenges, it is essential to integrate genetics into ophthalmology curricula.

Background/Objectives: Acanthamoeba keratitis (AK) is a rare but sight-threatening corneal infection. This study reviews the clinical profile, diagnostic pathways, treatment strategies, and outcomes of AK cases managed over a 34-year period. Methods: We conducted a retrospective analysis of 52 microbiologically AK cases from 1983 to 2017. Results: The mean age at presentation was 27.7 ± 9.4 years, with a female predominance (63.5%). The majority (82.7%) were contact lens users, almost exclusively soft lens wearers, with documented risk behaviors such as poor hygiene and sleeping with lenses. 44.2% were initially misdiagnosed as nonspecific microbial keratitis. Common clinical findings included epithelial defects (30.8%), ring infiltrates (44.2%), superficial infiltrates (53.8%), hypopyon (30.8%), and corneal thinning (13.5%). Diagnosis was confirmed by culture/stain in 61.5% of cases, while others required confocal microscopy or corneal biopsy. Co-infections with bacteria were noted in ~20%. Prior to referral, 82.7% of patients had received empirical topical therapy. At KKESH, all received dual anti-Acanthamoeba therapy, and 69.2% underwent surgical intervention, including tectonic PKP (46.2%) and optical PKP (19.2%). Visual acuity improved from a mean logMAR of 1.51 at presentation to 0.87 at last follow-up. Anti-Acanthamoeba therapy was discontinued in 95.9% of patients by the end of follow-up, with steroid use tapering from 61.5% at 3 months to 16.3% at final visit. Conclusions: Acanthamoeba keratitis in Saudi Arabia predominantly affects young female contact lens users and often presents with diagnostic delays and misclassification as herpetic or bacterial keratitis. Despite aggressive medical and surgical therapy, visual outcomes remain suboptimal in many cases.